No specific news briefing data was provided for this reporting cycle. This report is generated primarily in response to material institutional position changes in Pfizer Inc. (PFE) as reflected in the most recent 13F filings, alongside updated fundamental and macro data.
Pfizer's trailing twelve-month revenue stood at approximately $63.3 billion as of 2026-03-29, representing a year-over-year increase of 5.4%. Net income for the same period was $7.5 billion, producing a net margin of 11.8% and an operating margin of 35.4%. The P/E ratio was recorded at 19.82, while EPS declined 9.6% year-over-year. Cash on hand was $1.7 billion against total debt of $64.5 billion, reflecting a notably leveraged balance sheet [SEC 10-Q - PFE - 2026-03-29].
Institutional ownership data reveals divergent positioning among prominent managers. Citadel reduced its PFE position by 17%, while AQR Capital added 21% to its holdings and Millennium increased its stake by 9.9% [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Millennium - Q1 2026]. No insider transaction data was provided for this reporting period. The material shifts across multiple large institutional filers directly motivated the generation of this report.
The prevailing macroeconomic backdrop shows the 10-year US Treasury yield at 4.57% and the 2-year yield at 4.08%, producing a normal yield curve spread of approximately 49 basis points [FRED DGS10] [FRED DGS2]. This rate environment is relevant context for assessing the cost implications of Pfizer's $64.5 billion debt load and the broader conditions under which large-cap pharmaceutical equities are currently priced.